Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brekke

Showing results (131-140 of 1,141) with videos related to

Pageof 115
Sort By:
Community Mental Health Journal|February 16, 2015
Escape from Discrepancy: Self-Esteem and Quality of Life as Predictors of Current Suicidal Ideation Among Individuals with SchizophreniaAnthony Fulginiti, John S Brekke
Psychiatric Services (Washington, D.C.)|March 1, 2003
Rehab rounds: use of the Americans with Disabilities Act by young adults with schizophreniaDeborah Gioia, John S Brekke
Nature Reviews. Drug Discovery|January 2, 2003
Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryOle Henrik Brekke, Inger Sandlie
Transplantation Proceedings|October 1, 1987
Pancreatic transplant revascularization by dual arterial anastomosesI B Brekke, J Norstein
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 24, 1999
[How to improve the rate of organ donation for transplantation?]B Lien, I B Brekke
Current Topics in Behavioral Neurosciences|February 12, 2011
Assessing function and functional outcome in schizophreniaElizabeth Bromley, John S Brekke
Scandinavian Journal of Primary Health Care|September 5, 2009
Acute abdominal pain in general practice: tentative diagnoses and handling. A descriptive studyMette Brekke, Rune Krogh Eilertsen
Pediatric Diabetes|March 8, 2007
Vitamin D supplementation and diabetes-related autoimmunity in the ABIS studyHilde K Brekke, Johnny Ludvigsson
European Radiology|January 1, 1997
Iopentol (Imagopaque 300) compared with ioxaglate (Hexabrix 320) in knee arthrography. A clinical trial assessing immediate and late adverse events and diagnostic informationJ J Railhac, O Brekke
Journal of Health Economics|November 11, 2005
Direct to consumer advertising in pharmaceutical marketsKurt R Brekke, Michael Kuhn
Pageof 115

Showing results (131-140 of 1,141) with videos related to

Sort By:
Pageof 115
Community Mental Health Journal|February 16, 2015
Escape from Discrepancy: Self-Esteem and Quality of Life as Predictors of Current Suicidal Ideation Among Individuals with SchizophreniaAnthony Fulginiti, John S Brekke
Psychiatric Services (Washington, D.C.)|March 1, 2003
Rehab rounds: use of the Americans with Disabilities Act by young adults with schizophreniaDeborah Gioia, John S Brekke
Nature Reviews. Drug Discovery|January 2, 2003
Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryOle Henrik Brekke, Inger Sandlie
Transplantation Proceedings|October 1, 1987
Pancreatic transplant revascularization by dual arterial anastomosesI B Brekke, J Norstein
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 24, 1999
[How to improve the rate of organ donation for transplantation?]B Lien, I B Brekke
Current Topics in Behavioral Neurosciences|February 12, 2011
Assessing function and functional outcome in schizophreniaElizabeth Bromley, John S Brekke
Scandinavian Journal of Primary Health Care|September 5, 2009
Acute abdominal pain in general practice: tentative diagnoses and handling. A descriptive studyMette Brekke, Rune Krogh Eilertsen
Pediatric Diabetes|March 8, 2007
Vitamin D supplementation and diabetes-related autoimmunity in the ABIS studyHilde K Brekke, Johnny Ludvigsson
European Radiology|January 1, 1997
Iopentol (Imagopaque 300) compared with ioxaglate (Hexabrix 320) in knee arthrography. A clinical trial assessing immediate and late adverse events and diagnostic informationJ J Railhac, O Brekke
Journal of Health Economics|November 11, 2005
Direct to consumer advertising in pharmaceutical marketsKurt R Brekke, Michael Kuhn
Pageof 115